US10501E2019 - Common Stock
BRAINSTORM CELL THERAPEUTICS
NASDAQ:BCLI (4/29/2024, 4:51:24 PM)
0.5396
+0.01 (+0.95%)
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer’s disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimers disease (AD) and other neurodegenerative diseases. NurOwn, the Company’s cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its Phase III ALS and Phase II PMS clinical trials. Its wholly owned Israeli subsidiary, BrainStorm Cell Therapeutics Ltd., holds rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd. and two others.
BRAINSTORM CELL THERAPEUTICS
1325 Avenue Of Americas, 28th Floor
New York City NEW YORK 10019
P: 12014880460
CEO: Chaim Lebovits
Employees: 43
Website: https://brainstorm-cell.com/
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases,...
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
Get insights into the top gainers and losers of Tuesday's after-hours session.
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Here you can normally see the latest stock twits on BCLI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: